07/13/2026 20:30
Empire State Building Observation Deck Debuts New Family Bundle Ticket Options

The Empire State Building Observation Deck (ESBOD), atop the “World’s Most Famous Building,” announced today new ticket bundle options for families of all ages to save on their visit to the famed New York City landmark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713003884/en/Empire State Building Observation Deck Debuts New Family Bundle Ticket Options Groups of four who purchase the new Family Ticket Bundle can save up to 20...

07/17/2026 10:30
Aqemia and Sanofi Expand Their Research Collaboration

Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across prog...

07/03/2026 10:02
VeriSilicon Introduces CPP2000 Camera Post-Processing IP for Embodied Robotics and Mobile Vision Applications

VeriSilicon (688521.SH) today announced its high-performance CPP2000 Camera Post-Processing (CPP) IP, expanding the company’s Image Signal Processing (ISP) solutions with advanced post-processing capabilities. By improving image quality and visual perception in mobile imaging scenarios, CPP2000 enables more reliable vision performance in robotics, drones, and other mobile vision applications. CPP2000 integrates multiple image processing technologies and can further optimize YUV images output ...

CLIC-Bait: AFP, France Médias Monde, and Top Content Creators Join Forces to Tackle Disinformation

Agence France-Presse (AFP) with partners France Médias Monde and Oštro have entered the production phase of CLIC, a European social media initiative to tackle disinformation. By fusing the rigour of professional journalists with the massive reach of popular content creators, the aim is to widen the audience for fact-checking content.

Agence France-Presse (AFP) with partners France Médias Monde and Oštro have entered the production phase of CLIC, a European social media initiative to tackle disinformation. By fusing the rigour of professional journalists with the massive reach of popular content creators, the aim is to widen the audience for fact-checking content.
Anglais
07/07/2026 05:00
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns

Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns. This press release features multimedia. View the full release here: h...

07/09/2026 08:00
ROYC and PwC Sweden Collaborate to Digitalize Private Equity Structuring & Fund Operations

ROYC today announces a strategic collaboration with PwC Sweden to accelerate the digitalization of the GP value chain. The partnership brings together PwC Sweden's market-leading expertise in fund formation and structuring with ROYC’s platform capabilities, with the shared aim of compressing time-to-market, eliminating manual friction in early-phase workflows, and improving the client experience across the full fund lifecycle for fund managers operating across any jurisdiction. "Digitalizatio...

05/28/2026 10:28
Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)

Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526387210/en/ “FDA IND clearance is a pivotal step in our P...